COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS

PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
sinapultide, dipalmitoylphosphatidylcholine,
palmitoyl-oleyl phosphatidylglycerol and palmitic acid
for the treatment of meconium aspiration syndrome

On 19 September 2001, orphan designation (EU/3/01/054) was granted by the European Commission to Discovery Laboratories Inc., United Kingdom, for sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleyl phosphatidylglycerol and palmitic acid (Surfaxin) for the treatment of meconium aspiration syndrome.

What is meconium aspiration syndrome?
Meconium aspiration syndrome is a condition that affects newborns in consequence of inhalation of meconium (baby's first feces, ordinarily passed after birth) during delivery. Affected newborns develop respiratory distress (increasing difficulty in breathing) soon after birth. In brief, tiny air sacs called alveoli are located at the tips of the lungs’ smallest breathing tubes, called bronchi. The alveoli are responsible for passing oxygen into the blood. When meconium is aspirated in the lungs, oxygen cannot enter the alveoli, which means that oxygen is no longer getting into the blood. Because the lungs are inflamed and filled with fluid, it is increasingly difficult to take breaths. Furthermore, the inflammation in the lungs leads to scarring. The lungs eventually become stiff with scar tissue and breathing becomes very difficult. Meconium aspiration syndrome is potentially chronically debilitating and life threatening.

What are the methods of treatment available?
At the time of submission of the application for orphan drug designation, no authorised medicinal products were available in the European Union. However, several therapeutic methods are available such as mechanical breathing assistance and/or removal of meconium through suction of the area of the throat at the back of the mouth and the windpipe.
Satisfactory argumentation has been submitted by the sponsor to justify the assumption that sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleyl phosphatidylglycerol and palmitic acid might be of significant benefit for the treatment of meconium aspiration syndrome. The assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.

What is the estimated number of patients affected by the condition*?
According to the information provided by the sponsor, meconium aspiration syndrome was considered to affect about 9,400 persons in the European Union.

How is this medicinal product expected to act?
Lung surfactant is a protein and fat complex that coats and keeps open the alveoli of the lung, thus ensuring a stable surface for oxygen passage. Surfaxin is a synthetic lung surfactant and the sponsor’s hypothesis is that it will ultimately help the patient to take breaths more easily.
What is the stage of development of this medicinal product?
The effects of sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleyl phosphatidylglycerol and palmitic acid were evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials in patients with meconium aspiration syndrome were ongoing.

Sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleyl phosphatidylglycerol and palmitic acid was not marketed anywhere worldwide for treatment of meconium aspiration syndrome, at the time of submission. Orphan designation of sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleyl phosphatidylglycerol and palmitic acid was granted in United States for treatment of meconium aspiration syndrome in newborn infants, treatment of acute respiratory distress syndrome in adults and in premature infants.

According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 18 July 2001 a positive opinion recommending the grant of the above-mentioned designation.

Opinions on orphan medicinal products designations are based on the following cumulative criteria: (i) the seriousness of the condition, (ii) the existence or not of alternative methods of diagnosis, prevention or treatment and (iii) either the rarity of the condition (considered to affect not more than five in ten thousand persons in the Community) or the insufficient return of development investments.

Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.

For more information:
Sponsor’s contact details:
Discovery Laboratories, Inc
Fountain Court
32 Frances Road
Windsor
Berkshire SL4 3AA
United Kingdom
Telephone: +44 17 53 70 50 80
Telefax: +44 17 53 83 15 41
E-mail: cschaber@discoverylabs.com

Patients’ association contact point: Not available

*Disclaimer: The number of patients affected by the condition is estimated and assessed for the purpose of the designation, for a European Community population of 385,000,000 (Eurostat 2002) and may differ from the true number of patients affected by the condition. This estimate is based on available information and calculations presented by the sponsor at the time of the application.

©EMEA 2007
<table>
<thead>
<tr>
<th>Language</th>
<th>Active Ingredient</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>English</td>
<td>Sinapultide, dipalmitoylphosphatidylcholine, palmitoyloleoyl phosphatidylglycerol and palmitic acid</td>
<td>Treatment of Meconium Aspiration Syndrome</td>
</tr>
<tr>
<td>Danish</td>
<td>Sinapultid Dipalmitoylphosphatidylcholine, palmitoyloleoyl phosphatidylglycerol og palmitinsyre</td>
<td>Behandling af Meconium Aspiration Syndrome</td>
</tr>
<tr>
<td>Dutch</td>
<td>Sinapultide dipalmitoylphosphatidylcholine, palmitoyloleoyl phosphatidylglycerol en palmitinezuur</td>
<td>Behandeling van Meconium Aspiratie Syndroom</td>
</tr>
<tr>
<td>Finnish</td>
<td>Sinapultidi Dipalmitoilfosfatidylkoliini, palmitolioleoli fosfatidylglyseroli ja palmitiinhappo</td>
<td>Mekoniumaspiraatio-oireyhtymän hoito</td>
</tr>
<tr>
<td>French</td>
<td>Sinapultide, dipalmitoylphosphatidylcholine, palmitoyloleoyl phosphatidylglycerol et acide palmitique</td>
<td>Traitement de l’inhalation méconiale</td>
</tr>
<tr>
<td>German</td>
<td>Sinapultide Dipalmitoylphosphatidylcholin, Palmitoyloleoylphosphatidylglycerol und Palmitinsäure</td>
<td>Behandlung des Mekonium Aspirationssyndroms</td>
</tr>
<tr>
<td>Greek</td>
<td>Σιναπούλτιδη, διοφωσφατιδυλοχολίνη, παλμιτοϋλική-ελαιοϋλική φωσφατιδυλογλυκερόλη και παλμιτικό οξύ</td>
<td>Θεραπεία συνδρόμου εισροφήσεως μυκωνίου</td>
</tr>
<tr>
<td>Italian</td>
<td>Sinapultide, dipalmitoilfosfatidicolina, palmitoilooleoil fosfatidiglicerolo e acido palmitico</td>
<td>Trattamento della Sindrome da Aspirazione del Meconio</td>
</tr>
<tr>
<td>Portuguese</td>
<td>Sinapultide, dipalmitoilfosfatidicolina, palmitoilooleoilfosfatidiglicerol e ácido palmitico</td>
<td>Tratamento do sindrome de aspiração do meconio</td>
</tr>
<tr>
<td>Spanish</td>
<td>Sinapultida, dipalmitoilfosfatidicolina, palmitoilooleoilfosfatidiglicerol y ácido palmitico</td>
<td>Tratamiento del Síndrome de Aspiración del Meconio</td>
</tr>
<tr>
<td>Swedish</td>
<td>Sinapultid, Dipalmitoilfosfatidylkolin, palmityloleoylfosfatidylkolin och palmitinsyra</td>
<td>Behandling av mekoniumaspirationssyndrom</td>
</tr>
</tbody>
</table>